ArticleOphthalmology science2026
High-Dimensional Vitreous Proteomics Identifies Epigenetic Pathway Signatures in Vitreoretinal Lymphoma.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: In this study, we sought to characterize systems-level vitreous proteomic alterations associated with vitreoretinal lymphoma (VRL) and determine whether coordinated proteomic signatures associated with diffuse large B-cell lymphoma (DLBCL) biology are detectable within the intraocular microenvironment. Design: A cross-sectional observational study. Participants: We included 11 immunocompetent patients diagnosed with VRL (DLBCL subtype) and 4 patients with a macular hole to serve as the noninflammatory controls. Methods: Undiluted vitreous samples from 11 eyes with VRL and 4 control eyes were analyzed using the SomaScan 7K aptamer‑based proteomic platform (SomaLogic), enabling quantification of 6981 proteins from limited-volume specimens. Differential expression analysis was performed using empirical Bayes linear modeling with false discovery rate (FDR) correction, followed by Gene Ontology, Reactome, and gene set enrichment analyses. Main Outcome Measures: Differentially expressed vitreous proteins and enriched biological pathways in VRL and control samples. Results: Unbiased proteomic profiling revealed a distinct molecular signature in VRL vitreous samples, characterized by a coordinated enrichment of proteins associated with nuclear and chromatin-related pathways. A total of 2499 proteins met the predefined differential expression criteria (|log2-fold change| ≥ 0.5; adjusted Conclusions: Vitreoretinal lymphoma was characterized by enrichment of proteins associated with nuclear and epigenetic regulatory pathways and the relative suppression of extracellular structural pathways, suggesting substantial intraocular microenvironmental remodeling. These findings demonstrate that high-dimensional vitreous proteomics can capture proteomic features associated with lymphoma-related pathways and provide a framework for molecular characterization and biomarker discovery in intraocular lymphoma. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.